Journal article · 2016 · Open access
Alzheimer's drug‐development pipeline: 2016
Alzheimer s & Dementia Translational Research & Clinical Interventions, 2(4), 222–232 · Published 18 August 2016 · DOI 10.1016/j.trci.2016.07.001
In brief
“Alzheimer's drug‐development pipeline: 2016” is a 2016 journal article by Jeffrey L. Cummings and 2 co-authors, published in Alzheimer s & Dementia Translational Research & Clinical Interventions. OpenAlex counts 111 citations as of 15 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Alzheimer s & Dementia Translational Research & Clinical Interventions.
- Citations
- 111
- Most cited in
- 2017 (20)
- Field-weighted impact
- 6.82
- References
- 25
- Authors
- 3
Abstract
BACKGROUND: Alzheimer's disease (AD) is growing in frequency and new therapies are urgently needed. METHODS: We assessed clinicaltrials.gov (accessed 1-4-2016) to determine the number and characteristics of trials in phase I, phase II, and phase III for treatment of AD. RESULTS: There are currently 24 agents in 36 trials in phase III of AD drug development. Seven of these 24 agents are symptomatic cognitive-enhancing compounds, and 17 are disease-modifying treatments (DMTs). Most DMTs address amyloid-related targets (76%). There are 45 agents in phase II being assessed in 52 clinical trials. Phase II trials include 30 DMTs, with 26 small molecules and 4 immunotherapies. There are 24 agents in the first phase of AD drug development. DISCUSSION: Amyloid is the principal target of late-stage development programs. There are relatively few agents in clinical trials for AD suggesting a need to amplify the drug discovery ecosystem.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Cummings, J. L., Morstorf, T., & Lee, G. (2016). Alzheimer's drug‐development pipeline: 2016. Alzheimer s & Dementia Translational Research & Clinical Interventions, 2(4), 222–232. https://doi.org/10.1016/j.trci.2016.07.001
MLA 9
Cummings, Jeffrey L., et al. “Alzheimer's drug‐development pipeline: 2016.” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 2, no. 4, 2016, pp. 222–232. https://doi.org/10.1016/j.trci.2016.07.001.
Chicago
Cummings, Jeffrey L., Travis Morstorf, and Garam Lee. 2016. “Alzheimer's drug‐development pipeline: 2016.” Alzheimer s & Dementia Translational Research & Clinical Interventions 2 (4): 222–232. https://doi.org/10.1016/j.trci.2016.07.001.
Harvard
Cummings, J. L., Morstorf, T. and Lee, G. (2016) ‘Alzheimer's drug‐development pipeline: 2016’, Alzheimer s & Dementia Translational Research & Clinical Interventions, 2(4), pp. 222–232. doi:10.1016/j.trci.2016.07.001.
IEEE
J. L. Cummings, T. Morstorf, and G. Lee, “Alzheimer's drug‐development pipeline: 2016,” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 2, no. 4, pp. 222–232, 2016, doi: 10.1016/j.trci.2016.07.001.
BibTeX
@article{cummings2016alzheimer,
title = {{Alzheimer's drug‐development pipeline: 2016}},
author = {Cummings, Jeffrey L. and Morstorf, Travis and Lee, Garam},
journal = {Alzheimer s \& Dementia Translational Research \& Clinical Interventions},
year = {2016},
volume = {2},
number = {4},
pages = {222--232},
doi = {10.1016/j.trci.2016.07.001},
url = {https://doi.org/10.1016/j.trci.2016.07.001}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2017 | 20 | |
| 2018 | 20 | |
| 2019 | 16 | |
| 2020 | 13 | |
| 2021 | 5 | |
| 2022 | 17 | |
| 2023 | 3 | |
| 2024 | 8 | |
| 2025 | 3 | |
| 2026 | 5 |
Its field-weighted citation impact is 6.82: it has been cited 6.82 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Alzheimer's disease
- drug development pipeline
- clinical trials
- disease-modifying therapy
- amyloid
- immunotherapy
- small molecules
Work with this paper
Most-cited papers in Neuroscience
- The Rat Brain in Stereotaxic CoordinatesGeorge Paxinos, CHARLES R. R. WATSON · Elsevier eBooks · 1982 · 52,413 citations
- The assessment and analysis of handedness: The Edinburgh inventoryRichard Charles Oldfield · Neuropsychologia · 1971 · 36,725 citations
- EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysisArnaud Delorme A, Scott Makeig · Journal of Neuroscience Methods · 2004 · 25,302 citations
- The Ecological Approach to Visual PerceptionMarc H. Bornstein, James J. Gibson · Journal of Aesthetics and Art Criticism · 1980 · 22,977 citations
- The Psychophysics ToolboxDavid H. Brainard · Spatial Vision · 1997 · 20,208 citations
Questions about this paper
How do I cite this paper in APA style?
Cummings, J. L., Morstorf, T., & Lee, G. (2016). Alzheimer's drug‐development pipeline: 2016. Alzheimer s & Dementia Translational Research & Clinical Interventions, 2(4), 222–232. https://doi.org/10.1016/j.trci.2016.07.001
How many times has this paper been cited?
111 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Alzheimer s & Dementia Translational Research & Clinical Interventions.
Who wrote this paper?
Jeffrey L. Cummings, Travis Morstorf, Garam Lee.
What is the DOI of this paper?
10.1016/j.trci.2016.07.001. The permanent link is https://doi.org/10.1016/j.trci.2016.07.001.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.